Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial
Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...
Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...
Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...
MicroPort’s Talos Stent Gains Marketing Approval in Argentina
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...
Hainan Unveils 20 Measures to Boost Pharmaceutical Industry Reform and Quality
The General Office of the People’s Government of Hainan Province has released the “Implementation Plan...
Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development
China-based Minghui Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical....
EnChannel Medical Secures RMB 600 Million in Series B Funding for Electrophysiological Products
China-based EnChannel Medical Guangzhou Inc., a specialist in electrophysiology, has reportedly secured RMB 600 million...
Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...
Eli Lilly and Purdue Expand Partnership With $250 Million Investment
US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...
CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...
CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG
Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...
Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development
China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...
InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...
AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small...
IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma
China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...
Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...
RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...
NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million
Shenzhen-based XtalPi Holdings Limited (HKG: 2228) announced plans to acquire a 90% stake in Re...